CRIS

Curis, Inc. [CRIS] Stock Forecast

Q: What is Curis, Inc. stock symbol ?

Curis, Inc. is a US stock, located in Lexington of Ma and trading under the symbol CRIS

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CRIS Stock Summary

Earnings are expected to rise 9.77% next year

Currently unprofitable, and not expected to turn profitable in the coming year

CRIS has less than 1 year of cash runway

Top CRIS Correlated Resources

CRIS

Top 10 Correlated ETFs

CRIS

Top 10 Correlated Stocks

CRIS

In the News

09:04 10 Dec 2023 CRIS

Curis's stock rises as analysts see ‘the next Pharmacyclics'

Shares of Curis Inc. CRIS, +4.23% gained nearly 6% premarket on Friday after Truist Securities analysts initiated coverage of the cancer-focused biotech company with a buy rating.

02:32 10 Dec 2023 CRIS

Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript

Curis, Inc. (NASDAQ:CRIS ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Conference Call Participants Yale Jen - Laidlaw & Co. Operator Good morning, and welcome to Curis' Third Quarter 2023 Business Update Call. All participants will be in a listen-only mode.

08:13 10 Dec 2023 CRIS

Curis to Present at Upcoming Healthcare Conferences in September

LEXINGTON, Mass. , Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The H.C.

07:32 10 Dec 2023 CRIS

Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates

Curis (CRIS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.

06:25 10 Dec 2023 CRIS

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

LEXINGTON, Mass. , July 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that the Company will release its second quarter 2023 financial results on Thursday, August 3, 2023, after the close of U.S. markets.

07:01 10 Dec 2023 CRIS

Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates

Curis (CRIS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.18 per share a year ago.

08:00 10 Dec 2023 CRIS

Curis to Present at Upcoming Healthcare Conferences in April

LEXINGTON, Mass. , April 3, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The Cantor Fitzgerald Future of Oncology Symposium, being held virtually from April 3 – 5, 2023.

12:22 10 Dec 2023 CRIS

Curis, Inc. (CRIS) Q4 2022 Earnings Call Transcript

Curis, Inc. (NASDAQ:CRIS ) Q4 2022 Earnings Conference Call March 13, 2023 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer James Dentzer - President and Chief Executive Officer Robert Martell - Head of R&D Conference Call Participants Ed White - H.C. Wainwright Soumit Roy - JonesTrading Yale Jen - Laidlaw & Company Operator Good morning, and welcome to the Curis Fourth Quarter 2022 Business Update Call.

10:44 10 Dec 2023 CRIS

Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of 14.29% and 4.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

07:09 10 Dec 2023 CRIS

Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call

LEXINGTON, Mass. , March 8, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it is rescheduling its fourth quarter business update and quarterly investor conference call previously scheduled for Thursday, March 9, 2023 at 4:30 p.m.

CRIS Financial details

Company Rating

Buy

Market Cap

67.86M

Income

-48.07M

Revenue

10.21M

Book val./share

5.17

Cash/share

11.97

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

02 Nov 2023

P/E

-1.37

Forward P/E

-1.49

PEG

1.01

P/S

6.64

P/B

2.23

P/C

0.96

P/FCF

-2.21

Quick Ratio

5.73

Current Ratio

6.19

Debt / Equity

0.15

LT Debt / Equity

0.1

EPS (TTM)

-9.56

EPS next Y

-7.72

EPS next Q

-2.34

EPS this Y

16.82%

EPS next Y

-19.22%

EPS next 5Y

-24.06%

EPS last 5Y

-8.06%

Revenue last 5Y

-0.52%

Revenue Q/Q

28.95%

EPS Q/Q

-13.77%

SMA20

127.44%

SMA50

980.36%

SMA100

1357.83%

Inst Own

30.85%

Inst Trans

1.04%

ROA

-53%

ROE

-138%

ROC

-0.6%

Gross Margin

98%

Oper. Margin

-454%

Profit Margin

-471%

Payout

Shs Outstand

5.88M

Shs Float

4.86M

Target Price

52W Range

0.38-15.11

52W High

52W Low

RSI

60.52

Rel Volume

0.51

Avg Volume

158.02K

Volume

81K

Perf Week

-6.56%

Perf Month

184.94%

Perf Quarter

1290.36%

Perf Half Y

1290.36%

Beta

3.931

Volatility

1.27%, 3.14%

Prev Close

-12.77%

Price

11.54

Change

-9.7%

CRIS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	6.3	6.03	4.45	2.33	2.18
Net income per share	-19.67	-22.18	-14.33	-11.06	-12.92
Operating cash flow per share	-18.16	-15.8	-10.58	-8.22	-11.64
Free cash flow per share	-18.21	-15.82	-10.86	-8.22	-11.73
Cash per share	14.66	12.38	69.24	25.31	18.34
Book value per share	-2.72	-20.44	53.7	19.81	9.97
Tangible book value per share	-8.14	-25.85	50	17.85	8.05
Share holders equity per share	-2.72	-20.44	53.7	19.81	9.97
Interest debt per share	27.96	3.02	5.24	3.03	2.47
Market cap	1.14M	2.82M	19.93M	21.79M	2.57M
Enterprise value	12.99M	-12.44M	-102.02M	-13.18M	-10.35M
P/E ratio	-0.04	-0.08	-0.57	-0.43	-0.04
Price to sales ratio	0.11	0.28	1.84	2.05	0.25
POCF ratio	-0.04	-0.11	-0.77	-0.58	-0.05
PFCF ratio	-0.04	-0.11	-0.75	-0.58	-0.05
P/B Ratio	-0.25	-0.08	0.15	0.24	0.06
PTB ratio	-0.25	-0.08	0.15	0.24	0.06
EV to sales	1.25	-1.24	-9.42	-1.24	-1.02
Enterprise value over EBITDA	-0.45	0.52	4.11	0.32	0.2
EV to operating cash flow	-0.43	0.47	3.96	0.35	0.19
EV to free cash flow	-0.43	0.47	3.86	0.35	0.19
Earnings yield	-28.51	-13.05	-1.75	-2.32	-23.49
Free cash flow yield	-26.39	-9.31	-1.33	-1.73	-21.32
Debt to equity	-9.42	0	0.06	0.1	0.14
Debt to assets	1.13	0	0.04	0.06	0.06
Net debt to EBITDA	-0.41	0.64	4.91	0.85	0.24
Current ratio	4.25	3.78	12.84	8.08	6.96
Interest coverage	-7.47	-5.03	-4.89	-9.41	-11.11
Income quality	0.92	0.82	0.86	0.83	0.96
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.42	1.16	1.12	1.62	1.93
Research and developement to revenue	2.34	2.23	2.13	3.28	4.26
Intangibles to total assets	0.24	0.26	0.04	0.06	0.08
Capex to operating cash flow	0	0	0.03	0	0.01
Capex to revenue	-0.01	0	-0.06	0	-0.04
Capex to depreciation	-0.48	-0.33	-4.7	0	-1.79
Stock based compensation to revenue	0.38	0.27	0.25	0.5	0.66
Graham number	34.67	101.01	131.59	70.22	53.83
ROIC	-0.79	0.83	-0.2	-0.45	-0.99
Return on tangible assets	-1.15	-1.41	-0.18	-0.33	-0.6
Graham Net	-9.58	-27.78	39.81	9.92	5.16
Working capital	20.76M	18.22M	172.36M	126M	76.42M
Tangible asset value	-13.48M	-42.89M	121.69M	81.73M	37.57M
Net current asset value	-14.73M	-44.26M	113.23M	72.2M	26.94M
Invested capital	-9.42	0	0.06	0.1	0.14
Average receivables	2.97M	3.05M	3.14M	3.13M	3.1M
Average payables	4.17M	3.69M	4.32M	5.29M	4.81M
Average inventory	-413.5K	-460.5K	-246.5K	-1.47M	-2.71M
Days sales outstanding	100.25	118.36	102.51	110.5	106.86
Days payables outstanding	1.89K	3.24K	2.85K	4.39K	4.53K
Days of inventory on hand	-536.15	-68.21	-272.72	-1.74K	-4.1K
Receivables turnover	3.64	3.08	3.56	3.3	3.42
Payables turnover	0.19	0.11	0.13	0.08	0.08
Inventory turnover	-0.68	-5.35	-1.34	-0.21	-0.09
ROE	7.25	1.09	-0.27	-0.56	-1.3
Capex per share	-0.05	-0.02	-0.28	0	-0.09

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.6	0.6	0.48	0.45	0.5
Net income per share	-2.98	-2.58	-2.38	-2.47	-2.13
Operating cash flow per share	-2.8	-2.54	-2.53	-1.63	0.29
Free cash flow per share	-2.81	-2.54	-2.53	-1.63	0.29
Cash per share	21.04	17.76	14.85	13.13	11.97
Book value per share	11.89	9.66	7.57	5.42	5.17
Tangible book value per share	9.97	7.79	5.72	3.57	3.6
Share holders equity per share	11.89	9.66	7.57	5.42	5.17
Interest debt per share	1.11	1.74	1.26	0.83	0.76
Market cap	3.28M	2.65M	2.9M	4.01M	37.7M
Enterprise value	-22.37M	-10.27M	-25.12M	-12.43M	16.32M
P/E ratio	-0.06	-0.05	-0.06	-0.08	-0.77
Price to sales ratio	1.16	0.92	1.26	1.83	13.31
POCF ratio	-0.25	-0.22	-0.24	-0.51	23.09
PFCF ratio	-0.25	-0.22	-0.24	-0.51	23.09
P/B Ratio	0.06	0.06	0.08	0.15	1.27
PTB ratio	0.06	0.06	0.08	0.15	1.27
EV to sales	-7.92	-3.56	-10.94	-5.66	5.76
Enterprise value over EBITDA	1.83	1	2.16	1.1	-1.32
EV to operating cash flow	1.7	0.84	2.06	1.58	10
EV to free cash flow	1.7	0.84	2.06	1.58	10
Earnings yield	-4.26	-4.69	-3.96	-2.98	-0.32
Free cash flow yield	-4.01	-4.63	-4.21	-1.96	0.04
Debt to equity	0.08	0.14	0.17	0.13	0.15
Debt to assets	0.03	0.06	0.07	0.04	0.05
Net debt to EBITDA	2.1	1.26	2.41	1.46	1.73
Current ratio	7.69	6.96	7.07	7.01	6.19
Interest coverage	-12.32	-6.19	170.99	-19.03	0
Income quality	0.99	1.08	1.06	0.66	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.61	1.5	2.07	1.93	1.68
Research and developement to revenue	3.83	3.02	3.98	4.56	3.66
Intangibles to total assets	0.07	0.08	0.1	0.11	0.1
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	-0.02	0	0	0	0
Capex to depreciation	-0.85	0	0	0	0
Stock based compensation to revenue	0.47	0.6	0.61	0.65	0.58
Graham number	28.24	23.67	20.13	17.38	15.74
ROIC	-0.21	-0.2	-0.25	-0.39	-0.33
Return on tangible assets	-0.12	-0.12	-0.13	-0.16	-0.15
Graham Net	7.2	5	2.88	1.49	1.84
Working capital	91.98M	76.42M	64.15M	58.17M	64.65M
Tangible asset value	46.76M	37.57M	27.61M	17.24M	20.61M
Net current asset value	38.61M	26.94M	16.75M	9.77M	16.71M
Invested capital	0.08	0.14	0.17	0.13	0.15
Average receivables	2.64M	2.93M	2.64M	2.35M	2.62M
Average payables	5.63M	4.47M	2.92M	2.66M	3.95M
Average inventory	0	-1.44M	-3.09M	-1.65M	272K
Days sales outstanding	91.94	92.74	90.67	97.74	90.48
Days payables outstanding	8.36K	4.05K	9.91K	3.27K	7.83K
Days of inventory on hand	0	-3.66K	-12.38K	0	816
Receivables turnover	0.98	0.97	0.99	0.92	0.99
Payables turnover	0.01	0.02	0.01	0.03	0.01
Inventory turnover	0	-0.02	-0.01	0	0.11
ROE	-0.25	-0.27	-0.31	-0.46	-0.41
Capex per share	-0.01	0	0	0	0

CRIS Frequently Asked Questions

What is Curis, Inc. stock symbol ?

Curis, Inc. is a US stock , located in Lexington of Ma and trading under the symbol CRIS

What is Curis, Inc. stock quote today ?

Curis, Inc. stock price is $11.54 today.

Is Curis, Inc. stock public?

Yes, Curis, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 158.02K
Market Capitalization 67.86M
Employee 51
CEO Mr. James E. Dentzer
Headquarters Lexington,MA,US
IPO Date 2000-08-01
Website https://www.curis.com

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.